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Abstract: The vitamin folate is recognized as beneficial health-wise in the prevention of 
neural  tube  defects,  anemia,  cardiovascular  diseases,  poor  cognitive  performance,  and 
some forms of cancer. However, suboptimal dietary folate intake has been reported in a 
number  of  countries.  Several  national  health  authorities  have  therefore  introduced 
mandatory food fortification with synthetic folic acid, which is considered a convenient 
fortificant, being cost-efficient in production, more stable than natural food folate, and 
superior in terms of bioavailability and bioefficacy. Other countries have decided against 
fortification  due  to  the  ambiguous  role  of  synthetic  folic  acid  regarding  promotion  of 
subclinical cancers and other adverse health effects. This paper reviews recent studies on 
folate bioavailability after intervention with folate from food. Our conclusions were that 
limited folate bioavailability data are available for vegetables, fruits, cereal products, and 
fortified  foods,  and  that  it  is  difficult  to  evaluate  the  bioavailability  of  food  folate  or 
whether intervention with food folate improves folate status. We recommend revising the 
classical approach of using folic acid as a reference dose for estimating the plasma kinetics 
and relative bioavailability of food folate. 
Keywords:  folate;  folic  acid;  human  bioavailability;  intervention  trials;  post-dose  
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1. Introduction  
The preventive effect of high folic acid intake against neural tube defects (NTD) is considered one 
of the most important nutritional discoveries in the period 1976–2006 [1]. Folate requirements are 
increased in life stages with amplified cell division, e.g., during pregnancy, as folate is essential during 
cellular replication. It is assumed that on a population level, nutritional requirements for folate, as with 
those for vitamin D, cannot be completely covered by a ―varied diet‖, as recommended by national 
health authorities [2]. Dietary intake is below recommendations [3] in various Western societies owing 
to low consumption of folate-rich foods, e.g., pulses, citrus fruits, and leafy vegetables. It is estimated 
that an additional intake of 50–180 µg  folate would allow most to reach the recommendations [4]. 
Populations of low socio-economic status have limited access to folate-rich foods, and furthermore 
natural food folates are rather unstable molecules, so that average losses in vitamin activity of around 
30% can be expected during food processing [5]. However, the only risk factor for NTD which can be 
directly affected is inadequate dietary folate intake [6]. 
The chemically most stable folate form is synthetic folic acid [7], which is cheap to produce and 
therefore used for dietary supplements and food fortification. The introduction of folic acid-fortified 
staple  foods  has  effectively  decreased  the  prevalence  of  NTD,  e.g.,  in  the  USA  and  Canada  [8]. 
Significantly  improved  stroke  mortality  has  also  been  reported  [9].  In  most  countries,  the 
Recommended  Dietary Allowance (RDA)  for  folate  is  300  µg /day  for  adults  and  400  µ g/day  for 
women of childbearing age. With respect to vascular function, a folate intake according to the above 
recommendations has been shown to be beneficial, whereas higher doses do not provide any further 
health benefits [10]. The recommendations are more easily met by consumption of folic acid-fortified 
foods, owing to the higher stability and bioavailability of synthetic folic acid compared with native 
food  folates  [11].  The  bioavailability  of  food  folate  is  commonly  estimated  at  50%  of  folic  acid 
bioavailability when establishing food recommendations [2,12], but this should be considered a rough 
estimate, as data on the bioavailability of food folate vary between 30% [13] and 98% [14]. In the US, 
dietary recommendations are expressed in terms of Dietary Folate Equivalents (DFE) to account for 
differences in the bioavailability of native food folate and folic acid fortificant [12]. The discrepancies 
in folate bioavailability estimates are caused by the nature of the test food or meal (as thoroughly 
reviewed  [15,16]),  entrapping  the  vitamin  and  affecting  stability  and  absorption,  inter-subject 
variation, different study designs and, as recently suggested, metabolic inequities between different 
folate forms with respect to post-absorption plasma kinetics in the human metabolism [17–19]. Another 
important aspect is that the interpretation of bioavailability data is hampered by large methodological 
differences during folate quantification in clinical samples and test foods, which is complicated by lack 
of standardized reference methods for sample preparation and folate quantification, internal standards, 
and  use  of  certified  reference  material  [20–22].  Recent  publications  question  the  validity  of  the 
conventional approach used in bioavailability studies comparing folic acid with natural food folate [19], 
and demand approaches using whole diets rather than single foods [11] or data from meta-analyses of 
controlled feeding trials [23] in order to closer elucidate post-absorptive metabolism of the different 
folate forms. This is considered necessary for evaluating the adequacy of US RDA for folate [23], and 
also for estimating potential risks from mandatory folic acid fortification, as a high intake of synthetic 
folic acid is suggested to accelerate the development of, e.g., colorectal cancer [24–26].  Nutrients 2011, 3  
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2. Synopsis of Post-Absorptive Folate Metabolism 
It  is  commonly  assumed  that  food  folates,  which  mainly  exist  in  their  polyglutamyl  form,  are 
absorbed in the jejunum as monoglutamyl folates after removal of the polyglutamyl chain by intestinal 
γ-glutamyl hydrolase [27], and thereafter reduced and methylated in the enterocyte. Passive diffusion 
across the cell membrane is limited [28], and occurs only at high doses. To a minor extent folate is also 
absorbed in the colon; and it is suggested that colonic absorption may contribute significantly to total 
folate absorption [29], but it is unknown how relevant this is for maintaining folate status. However, it 
has  been  shown  for  humans  [29,30]  and  pigs  [31]  that  folates  synthesized  by  colon  bacteria  are 
bioavailable. Absorbed folate is transported to the liver, which contains about half the body pool of 
folate [32,33] and retains 10–20% of absorbed folate due to the first-pass effect [15], while the rest is 
transported  via  the  systemic  circulation  to  body  tissues.  Some  liver  folate  participates  in  the 
enterohepatic circulation and is secreted into bile [33,34]. However, most biliary folate is reabsorbed, 
supposedly to moderate between-meal fluctuations in folate supply to cells [34].  
In the cell nucleus, tetrahydrofolate-polyglutamate (H4-folate) is the substrate for both nucleotide 
synthesis and the methylation cycle (Figure 1), by providing or accepting one-carbon atoms [35].  
5-methyltetrahydrofolate (5-CH3-H4folate) donates a methyl group to vitamin B12, which transfers it 
to homocysteine, avoiding accumulation of homocysteine in the cell and maintaining synthesis of 
amino acids. The first signs of deficiency appear in tissues with rapid cell turnover and during life 
stages with increased cell division, such as pregnancy or growth [36], and can result in megaloblastic 
anemia by impaired synthesis of red blood cells [33].  
Figure  1.  Role  of  folate  in  nucleotide  synthesis  and  the  methylation  cycle  (adapted  
from  [37]).  Enzymes  are  shaded  and  their  end-products  marked  with  boxes.  Adapted  
from [38], p. 19.  
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BHMT:  betaine-homocysteine  methyltransferase;  DHFR:  dihydrofolate  reductase;  
DMG: dimethylglycine; MS: methionine synthase; MTHFR: methylenetetrahydrofolate reductase; 
TMP: thymidine monophosphate; TS: thymidylate synthase; UMP: uridine monophosphate. 
It is estimated that about 0.3–0.8% of the folate pool is excreted daily, mainly in the form of 
catabolites not affected by intake [32,39]. Renal excretion of intact folate is as low as ~5% after 
physiological doses [34,40–42], but it increases at higher folate intake [37]. In human feces, about 
400 nmol/day folate can be found, originating mainly from bacterial production, lysed enterocytes, and Nutrients 2011, 3  
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gastrointestinal secretions (e.g., bile) [34,43]. Little to at most 20% of fecal folate is estimated to 
derive from non-absorbed food folate [34,44–47].  
Genetic polymorphisms of key enzymes and carriers can affect cellular folate metabolism and result 
in  decreased  enzyme  activity,  increased  folate  requirements  [48–50],  and  an  increased  risk  of  
NTD  [51].  Furthermore,  vitamin  B12  deficiency  reduces  the  activity  of  methionine  synthase  
(MS;  Figure  1),  resulting  in  cellular  accumulation  of  homocysteine  and  5-methyltetrahydrofolate 
according to the methyl trap theory [37].  
3. Estimation of Folate Bioavailability—Still a Challenge 
Accurate estimation of dietary folate bioavailability is a prerequisite for the formulation of nutrition 
recommendations, but is still a challenge. Folate absorption is defined as the in vivo process by which 
folate proceeds from the site of administration to the site of measurement (usually plasma) [52]. Folate 
bioavailability  is  defined  as  the  fraction  of  ingested  folate  that  is  absorbed  and  can  be  used  for 
metabolic processes [16]. Findings from early bioavailability studies until the mid-1990s discussed by 
others indicate the need for further investigations on folate bioavailability and influencing factors [53]. 
Long-term  (Tables  1  and  2)  and  short-term  (Table  3)  human  trials,  conducted  during  the  past 
15 years, have produced inconclusive findings regarding dietary folate bioavailability, complicating 
the  interpretation  of  data  by  different  definitions  for  the  term  bioavailability  and  differing  study 
designs. Furthermore, difficulties with respect to the exact quantification of ingested folate dose from 
food samples and in clinical samples limit the validity of many studies [19,54]. Although there are 
recommendations  for  the  extraction  of  food  samples  using  trienzyme  treatment  [55–57],  this  
approach  is  used  in  only  some  studies  [13,14,45,58–64].  Others  apply  dienzyme  [46]  or 
monoenzyme [18,40,42,65] extraction prior to folate quantification by microbiological assay or HPLC 
(LC-MS  or  LC-FLD).  Information  is  sometimes  missing  [17,66,67],  or  dietary  folate  doses  are 
determined by calculation [19,68–70] (Tables l–3). 
Table 1. Dietary folate intervention trials resulting in no significant effects (presented as 
change (%) compared with baseline) on folate status. 
Intervention 
diet 
Folate intake  W  N  Age  Erythrocyte folate  p/s-folate  tHcy (µ mol/L) 
Ref.  Dose (µ g/day) 
(Q) 
1 
Total 
2 
(µ g/day) 
     
Baseline 
(nmol/L) 
End 
(%) 
Baseline 
(nmol/L) 
End 
(%) 
Baseline 
(nmol/L) 
End 
(%) 
Control  2 (C) 
1    4  35, F  41 ±  3 
3      15 ±  9 
3  −15  11 ±  4 
3  −10  [68] 
5-a-day fruit/veg  43 (C) 
1    4  36, F  42 ±  4 
3      17 ±  9 
3  −6  10 ±  3 
3  0   
Control  0 (T) 
1  186  4  18, M  23–39 
4      16 ±  9 
3  −7  12 ±  4 
3  0  [13] 
Spinach  200 (T) 
1  384  4  18, M  23–39 
4      14 ±  5 
3  −7  12 ±  3 
3  0   
Yeast  200 (T) 
1  411  4  19, M  23–39 
4      15 ±  7 
3  −17  12 ±  3 
3  −9   
Control  23 (L) 
1  210  12  9, F  17–40 
4  709 ±  157 
3,5  +3 
5          [66] 
High folate diet  201 (L) 
1  410  12  10, F  17–40 
4  797 ±  200 
3,5  +7 
5           
F: females; M: males; W: weeks; N: number of subjects; Veg: vegetables; p/s-folate: plasma/serum folate concentration; tHcy: total 
homocysteine concentration in plasma/serum; End (%): relative increase (+) or decrease (−) in status parameter at end of intervention 
compared with baseline. 
1 Q: Quantification of folate content in intervention doses by (C: calculation, T: using trienzyme extraction,  
L: lacking information); 
2 Estimated by dietary recall (either reported as total folate intake or estimated as dose + folate intake at screening);  
3 Mean ±  SD; 
4 Age reported as inclusion criteria; 
5 Erythrocyte folate concentrations given in µ g/L, calculated to nmol/L (0.460
−1 nmol/µ g). Nutrients 2011, 3  
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Table 2. Dietary folate intervention trials resulting in significant effects (presented as change (%) compared with baseline) on folate status.  
Intervention diet 
Folate intake (µ g/day)  W  N 
2  Age  Erythrocyte folate  p/s-folate  tHcy 
Ref. 
Dose (Q) 
1  Total
        Baseline (nmol/L)  End (%)  Baseline (nmol/L)  End (%)  Baseline (µ mol/L)  End (%) 
Control  0   236  16  43  -      26 ±  8 
3  −4  9 ±  3 
3  0  [69] 
5-a-day fruit/vegetables  63 (C)  306  16  41  -      26 ±  7 
3  +7 
♦  10 ±  4 
3  −11   
Low folate diet   0 (L)  131  4  23  50 ±  4 
3      13 ±  6 
3  −8  14 ±  6 
3  −8  [67] 
500 g fruit and vegetables   97 (L)  228  4  24  49 ±  6 
3      16 ±  10 
3  0 
♦  12 ±  4 
3  −9 
♦   
Control  0   239  12  17, F  48 (38, 57) 
7  900 (647, 1079) 
7  −22 
7  12 (11, 15)  0 
7  9 (7, 11)  +10 
7  [59] 
5 slices bread  70 (T)  379  12  17, F  47 (40, 55) 
7  855 (635, 992) 
7  −18  12 (9–16)  0  9 (8, 11)  −21 *   
Breakfast (SNO [71])  125 (T)  437  12  17, F  49 (35, 53) 
7  805 (742, 909) 
7  +12 
♦  12 (10, 16)  +8  7 (7, 9)  −23 *
,♦   
Folic acid-fortified bread   188 (T)  461  4  31  36 ±  13 
3  606 ±  224 
3  +13 *  12 ±  5 
3  +25 *      [60] 
Rye and orange juice  184 (T)  461  4  33  36 ±  13 
3  561 ±  190 
3  +15 *  10 ±  3 
3  +23 *       
Folic acid  150 (T)  221 
4  4  15  19–48 
5      12 ±  4 
3  +20  10 ±  2 
3  −11  [61] 
Vegetables, fruits, liver pate  331 (T)  427 
4  4  29  19–41 
5      12 ±  4 
3  +33 
♦  10 ±  3 
3  −11   
Placebo  0   ~360 
9  16  43  46 ±  2  895 ±6  0  +3  26 ±2    −1  9 ±  0.4  0  [19] 
Food group  200 (C)  ~305 
9  16  38  45 ±  2  872 ±  61  +14 
♦  25 ±  2  +19 
♦  10 ±  1  −6 
♦   
5-methyltetrahydrofolate caps  200 (P)  ~295 
9  16  42  45 ±  2  793 ±  42  +30 
♦  22 ±  2  +41 
♦  10 ±  1  −14 
♦   
Folic acid caps  200 (P)  ~325 
9  16  40  48 ±  2  833 ±  56  +28 
♦  24 ±  2  +44 
♦  9 ±  0.4  −15 
♦   
Control  0 
  210 
4  4  22  23 ±  8 
3  347 ±  79
3  −1  13 ±  3 
3  0  10 ±  3
3  +9  [14] 
Fruit and vegetables   350 (T)  560 
4  4  23  23 ±  8 
3  338 ±  81
3  +16 
♦  14 ±  3 
3  +30 
♦  11 ±  5
3  −10 
♦   
Control  0 (T)  242  4  14  60 ±  15 
3      18 (15–22) 
6  0 
6  14 (12–16) 
6  0 
6  [62] 
High folate diet  355 (T)  618  4  20  58 ±  18 
3      18 (16–19) 
6  28 
6,♦  12 (11–13) 
6  −9 
6,♦   
Control  0 (T)  227  12  15  36–71 
8  539 ±  166 
3  0  15 (12–18) 
6  −7 
6  12 (11–14) 
6  0 
6  [58] 
High folate diet  ~350 (T)  707  12  15  36–71 
8  571 ±  162 
3  +11  15 (13–17) 
6  +32 
6,♦  11 (9–12) 
6  −10 
6   
Pericarp flour bread   223 (T)  436  16  25  48–56 
5  497 (414–581) 
6  +14 
6  13 (11–15) 
6  +7 
6  10 (8–11) 
6  −25 
6  [63] 
Aleurone flour bread   615 (T)  836  16  25  46–54 
5  509 (434–584) 
6  +34 
6,♦  13 (10–16) 
6  +52 
6,♦  9 (8–10) 
6  −29 
6,♦   
W: week; caps: capsules; N: number of subjects; F: females; p/s-folate: plasma/serum folate concentration; tHcy: total homocysteine concentration in plasma/serum. End (%): relative increase (+) or decrease (−) in 
status parameter at end of intervention compared with baseline. 
1 Q: Quantification of folate content in intervention doses by (C: calculation, T: using trienzyme extraction, L: lacking information); P: as provided by 
manufacturer; 
2 Females and males; 
3 Mean ±  SD; 
4 Folate dose analyzed and not estimated by dietary recall; 
5 Range; 
6 Geometric means (95% CI); 
7 Median (quartile 1, quartile 3); 
8 Age reported as inclusion 
criteria; 
9 Folate intake given in nmol, calculated to µg  (0.460
−1 nmol/µg). * Significant effect within the group compared with baseline (P < 0.05); 
♦ Significant effect compared with control (P < 0.05). Nutrients 2011, 3  
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Table 3. Trials using plasma concentration to assess the bioavailability of food folates or fortificants.  
  Dose 
nmol 
1 
AUC or App 
Abs 
2 
Sampling duration 
(nr/4 h) 
3 
Females 
+ males 
Age 
4  Ref. 
Size of AUC (h∙nmol/L) from supplements and fortified foods 
[
13C6]-folic acid  634  19  8 h (8)  10 
10  31 ±  1  [17] 
Folic acid 
5  1134  146
  10 h (6)  0 + 13  26 ±  6  [64] 
Folic acid 
  1134  40   10 h (6)  6 + 6  36–69  [45] 
Folic acid
  1193  37, 49 
7  7 h (3)  8 + 8  20–50  [65] 
Folic acid  907  62  10 h (4)  10 + 10  27 ±  3  [70] 
[
13C5]-folic acid in bread  450 (D)  28  12 h (7)  5 + 3  39–66  [46] 
[
13C5]-folic acid in breakfast meal  450 (D)  26  12 h (7)  5 + 3  39–66  [46] 
(6S)-[
13C6]-5-HCO-H4folate  500  42
  8 h (8)  10 
10  31 ±  1  [17] 
(6S)-5-CH3-H4folate 
5  1088  142  10 h (6)  0 + 13  26 ±  6  [64] 
(6S)-5-CH3-H4folate 
5  830 
6  44, 88 
6  10 h (7)  0 + 2  55, 77  [40] 
(6S)-5-CH3-H4folate i.m. 
5  830 
6  111, 144 
6  10 h (7)  0 + 2  55, 77  [40] 
(6S)-[
13C5]-5-CH3-H4folate in bread  450 (D)  66  12 h (7)  5 + 3  39–66  [46] 
Size of AUC (h∙nmol/L) from native food folates 
Broccoli 
5  440 (M)  27, 41 
6  10 h (7)  0 + 2  55, 77  [40] 
Strawberries 
5  450 (M)  32, 41 
6  10 h (7)  0 + 2  55, 77  [40] 
Spinach, monoglutamate 
8  820 (T)  31  10 h (6)  6 + 6  36–69  [45] 
Spinach, polyglutamate 
9   990 (T)  27  10 h (6)  6 + 6  36–69  [45] 
Spinach   544 (C) 
1088 (C) 
41 
71  
10 h (4)  10 + 10  27 ±  3  [70] 
Aleurone flour   1167 (M)  46, 38 
7  7 h (3)  8 + 8  20–50  [65] 
Wheat bran   213 (M)  8, 6 
7   7 h (3)  8 + 8  20–50  [65] 
Apparent absorption (%) from supplements, fortified foods and food folate 
[
13C6]-folic acid
  634  24%  8 h (8)  14 
10  33 ±  2  [18] 
(6S)-[
13C6]-5-HCO-H4folate  500  38%
  8 h (8)  14 
10  33 ±  2  [18] 
Spinach [
15N1–7]folate   588 (M)  44%
  8 h (8)  14 
10  33 ±  2  [18] 
Folic acid in bread 
5   491 
6 (M)  74%  10 h (7)  1 + 8  51–79  [44] 
(6S)-5-CH3-H4folate in fermented milk 
5   450 
6 (M)  86%  10 h (7)  1 + 8  51–79  [44] 
Yeast folate 
5  155 
6 (M)  80%  10 h (7)  1 + 8  51–79  [44] 
5-HCO-H4folate: 5-formyltetrahydrofolate; 5-CH3-H4folate: 5-methyltetrahydrofolate; [
13C5]-, [
13C6]-: stable isotope-labeled 
(5 or 6 
13C); (6S)-: bioactive folate diastereoisomer; 
1 Folate content in food intervention doses quantified by (T: trienzyme, 
D: dienzyme or M: Monoenzyme extraction, or by C: calculation); 
2 App abs: apparent absorption, estimated by (kinetic 
modeling [18,42] or AUC: area under the curve (Mean or Median)); 
3 Number of sampling occasions during 0–4 h post-dose 
in brackets; 
4 Mean ±  SD or range; 
5 Presaturation with ~1 mg [38,42] or 5 mg [72] folic acid/day from day −9 to day −2 
prior to each test day; 
6 Conversion factors from µg  to nmol: 0.441
−1 nmol/µ g (folic acid) and 0.460
−1 nmol/µ g (plasma 
folate and 5-methyltetrahydrofolate); 
7 Females and males reported separately; 
8 Folate monoglutamates from enzymatic 
cleavage of endogenous spinach folates after cell disruption; 
9 Native spinach folate polyglutamates; 
10 No data on gender. 
3.1. Intervention Trials 
Physiological  effects  of  dietary  folate  interventions  are  commonly  studied  in  4–6  week  trials 
assessing changes in one or several folate status parameters, e.g., fasting serum folate, erythrocyte 
folate, and plasma total homocysteine (Tables 1 and 2).  Nutrients 2011, 3  
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It seems appropriate to assess more than one status parameter, since the sensitivity of parameters 
and the rapidity of response varies. For example, a 4-week intervention study found the estimated 
bioavailability  of  food  folate  compared  with  folic  acid  to  be  78%  based  on  serum  folate  
concentrations, 98% based on erythrocyte folate concentrations, and only 60% based on homocysteine 
concentrations [14]. It is recommended that the appropriateness of the chosen status parameters in 
intervention trials be evaluated based on reliability coefficients [73–75]. Reliability coefficients show 
the ratio of between-subject variability to total variability, including the variability of the analytical 
method. Reliability coefficients for the common response parameters in folate intervention studies are 
within the range 0.65–0.97 [38,73–75].  
Interpretation of the effects of intervention on folate status and bioavailability is further complicated 
due to the fact that several genetic polymorphisms of folate/homocysteine metabolic enzymes may 
affect the individual parameters differently [72,76].  
Several intervention trials report a low relative bioavailability of food folates compared with folic 
acid  (Tables  1  and  2)  [13,58,66].  On  the  other  hand,  improvement  of  folate  status  parameters  
from food folates has been observed compared with a control group receiving no additional folate  
(Table 2) [59,67].  
Data from a very recent study [19] show that the relative response of folate status parameters after 
food intervention differs compared with a reference group receiving supplemental folic acid or the 
bioactive diastereoisomer (6S)-5-methyltetrahydrofolate (Metafolin
®). As the intervention with folic 
acid  results  in  a  greater  increase  in  fasting  plasma  folate  concentrations  than  bioactive  folate 
diastereoisomer, the estimated relative bioavailability of food folate is lower when compared with the 
supplemental folic acid receiving control group. Those authors therefore recommend avoiding using 
folic  acid  as  the  reference  dose  in  long-term  studies.  However,  this  hypothesis  remains  to  be 
confirmed, as some intervention trials with foods have resulted in similar improvements of folate status 
compared with equimolar or smaller doses of folic acid from fortified foods or supplements [60,61,63]. 
3.2. Short-Term Trials 
Short-term absorption or bioavailability of food folate has been found to be incomplete compared 
with that of folic acid [77], and as a result a number of approaches for assessment are now used.  
The plasma area under the curve (AUC) approach is based on the assumption that with standardized 
study design, the post-dose plasma folate concentrations over time correspond to the folate fraction 
absorbed from a single dose. Relative folate absorption is commonly assessed, comparing the test dose 
with an oral reference dose of supplemental folate, often folic acid (Table 3). Comparisons of the 
relative AUC after a single dose of supplemental folic acid and reduced folates show that the trials 
using presaturation of volunteer’s body stores [40,44,64] result in greater AUCs than others. This 
suggests that after administration of an oral dose, the amount of folate in peripheral plasma is affected 
by the hepatic first-pass effect and volunteer’s body stores, which could explain the variable results in 
published  bioavailability  data.  The  data  are  too  few  to  systematically  evaluate  whether equimolar 
doses of folic acid and reduced folate result in differently sized plasma AUCs, as administered doses, 
sampling intervals, number of sampling occasions, and presaturation of volunteers vary between trials 
(Table 3).  Nutrients 2011, 3  
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In three previous trials [18,45,70], the AUC or apparent absorption of spinach folate was estimated 
to be similar or greater than almost equimolar doses of synthetic folic acid, demonstrating in theory 
similar bioavailability. However, it was hypothesized that reduced folates and folic acid show differing 
plasma and distribution kinetics [17,18]. It was suggested that the initial site of folic acid metabolism 
is not the enterocyte, as accepted in the past, but the liver cell, and liver enzymes are postulated to have 
a greater affinity for oxidized folic acid than reduced folates. Therefore it is not considered appropriate 
to compare natural folate test doses (e.g., 5-methyltetrahydrofolate, 5-formyltetrahydrofolate) with a 
folic acid reference dose [18].  
With the aim of estimating absolute folate absorption and avoiding complications from differing 
plasma kinetics from test and reference compounds, a reference dose of the bioactive diastereoisomer 
(6S)-5-methyltetrahydrofolate, administered by intramuscular injection to bypass the liver, was used to 
estimate the bioavailability of native folate from foods [40]. In this pilot trial with only two volunteers, 
the AUCs from intramuscularly administered (6S)-5-methyltetrahydrofolate were greater than those 
from an oral dose of the same compound (Table 3), indicating partial hepatic retention of the orally 
administered folate dose even when volunteers were presaturated.  
In some trials the apparent absorption accounting for the folate distribution volume in the body has 
been  determined  using  biokinetic  modeling,  and  these  estimated  that  24–86%  of  supplemental  or 
native food folate is absorbed (Table 3) [18,44]. Some studies [78] are limited by too short post-dose 
plasma  sampling,  so  that  the  AUC  cannot  be  estimated  and  extrapolated  for  exact  assessment  of 
absorbed folate, or no plasma AUC data are provided [42,79].  
The  determination  of  folate  bioavailability  by  urinary  folate  excretion  ratio  is  based  on  the 
hypothesis that urinary excretion of [
13C]-labeled folate from an oral dose corresponds to that of a 
differently labeled reference dose of [
2H]-folic acid from analogous intravenous administration. This 
dual-label stable isotope protocol, when used to determine relative folate bioavailability of food folates 
and  added  fortificants,  produces  values  of  37–153%  [41,42,80–82].  However,  these  studies  also 
generated the information that reduced folates and folic acid are handled differently by the body; and 
(6S)-5-methyltetrahydrofolate was recommended as the reference dose [80].  
Studies using the oral-fecal balance technique for folate are commonly carried out using ileostomy 
subjects, who do not possess a colon microflora affecting fecal folate content, in combination with the 
AUC technique. Absorbed folate is inversely correlated to folate content in stomal effluent. However, 
not  all  folate,  found  in  ileostomy  effluent  or  feces,  originates  from  non-absorbed  orally  ingested 
folate [43], and therefore baseline folate excretion has to be assessed. Baseline folate excretion is 
determined either on a folate-free study day using a standardized protocol [40,44], or after a known 
reference dose of synthetic folic acid [45]. The use of stable isotope labeling allows folate from the 
dose to be distinguished from endogenous folate [34,83]. Folate bioavailability from foods and a meal 
has been estimated to be 50–90% using the balance technique [30,44–46,84].  
A common criticism of short-term protocols is the use of non-physiological doses, or large portions 
of test foods that are not likely to be consumed in a meal by the general population, e.g., 30 g of 
yeast [77] or 500 g of spinach [70], to overcome insufficient sensitivity of the model. To improve 
sensitivity and minimize or standardize hepatic retention of absorbed folate at first passage, folate body 
stores can be presaturated with supplemental folic acid [77] (Table 3). However, this approach can also Nutrients 2011, 3  
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be questioned, as it has been shown in vitro that high exposure to folic acid reduces cellular uptake into 
Caco-2 and kidney cells by down-regulation of genes coding for folate absorption and transport [85].  
A recent study uses a combined approach of various short-term techniques in the form of a stable 
isotope AUC and ileostomy model [46,47] to determine acute absorption of equimolar doses of either 
stable isotope-labeled (6S)-[
13C5]5-methyltetrahydrofolate or [
13C5]folic acid from bread or a breakfast 
meal (Table 3). The plasma AUC of labeled folate after ingestion of the bread fortified with bioactive 
(6S)-[
13C5]5-methyltetrahydrofolate  was  twice  that  for  food  labeled  with  folic  acid,  whereas  the 
excretion  of  labeled  folate  into  ileostomy  effluent  did  not  differ  significantly  and  was  as  low  as  
10% of the dose, indicating high bioavailability providing that no severe oxidative degradation of  
non-absorbed  labeled  folate  occurred  in  frequently  sampled  ileostomy  effluent.  For  supplemental  
(6S)-[
13C5]5-methyltetrahydrofolate too, a greater median plasma AUC was observed compared with 
[
13C5]folic acid [86] (Figure 2). 
These findings confirm the hypothesis of different metabolic handling of reduced folates and folic 
acid in the human body. The consequence is a recommendation to revise the classical approach of 
using folic acid as the reference dose for estimation of the plasma kinetics and relative bioavailability 
of food folate.  
Figure  2. Dose-normalized AUC of plasma [
13C5]5-methyltetrahydrofolate (h* nmol/L) 
after  single  oral  equimolar  folate  doses  (≈450  nmol  =  200  µ g)  in  the  form  of 
pharmaceutical  preparation  with  (6S)-[
13C5]5-methyltetrahydrofolate  (MTHF,  green)  or 
[
13C5]folic acid (PGA, green) or as bread fortified with (6S)-[
13C5]5-methyltetrahydrofolate 
(bread with MTHF, orange) or [
13C5]folic (bread with PGA, orange). * indicates an outlier. 
Data from [46,86].  
 
Even when the use of stable isotope-labeled folates (Table 3) offers the advantage of distinguishing 
between  labeled  folate  from  the  dose  and  unlabeled  endogenous  folate  [17,19,42,46],  no  data  on 
absorption of native food folates are obtained unless intrinsic labeling is used [18].  
Current short-term folate bioavailability data are therefore limited to a few vegetables, fruits, cereal 
products, and fortified foods (Table 3) [18,40,45,65,70,78] and have to be interpreted with caution. Nutrients 2011, 3  
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4. Conclusions  
This  summary  of  existing  information  shows  that  only  limited  folate  bioavailability  data  are 
available for vegetables, fruits, cereal products and fortified foods. It also shows the difficulties in 
assessment. No safe conclusion can be drawn as to whether intervention with food folate results in 
improved folate status. Additionally, it is not possible to estimate the size of the required minimum 
intervention dose of food folate to achieve improvement of status, as the status parameters are affected 
to different extents.  
However, the data highlight differences in the metabolic handling of folic acid and reduced folates 
in humans, as evidenced by differing acute post-absorptive plasma kinetics and different effects on 
fasting  plasma  folate  concentrations  after  long-term  intervention.  It  is  still  unclear  whether  these 
findings have implications for human health, and they need to be considered in recommendations 
regarding folic acid fortification of food. As it is not expected that the more expensive and less stable 
bioactive  diastereoisomer  (6S)-5-methyltetrahydrofolate  (Metafolin
®)  will  be  commonly  used  for 
fortification  purposes,  synthetic  folic  acid  reference  doses  are  appropriate  for  evaluation  of  the 
effectiveness of folic acid-fortified foods at population level. 
An immediate consequence is our recommendation to revise the classical approach of using folic 
acid as the reference dose in estimating the plasma kinetics and relative bioavailability of food folate. 
The design of future studies on relative folate bioavailability faces the challenge of accounting for the 
bias  from  metabolic  handling  of  folate  compounds,  and  existing  findings  have  to  be  interpreted  
with caution.  
References  
1.  Katan, M.B.; Boekschoten, M.V.; Connor, W.E.; Mensink, R.P.; Seidell, J.; Vessby, B.; Willett, W. 
Which Are the Greatest Recent Discoveries and the Greatest Future Challenges in Nutrition? Eur. 
J. Clin. Nutr. 2009, 63, 2–10.  
2.  NNR. Nordic Nutrition Recommendations NNR 2004 Integrating Nutrition and Physical Activity; 
Nordic Council of Ministers: Stockholm, Sweden, 2005.  
3.  Dhonukshe-Rutten, R.A.M.; de Vries, J.H.M.; de Bree, A.; van der Put, N.; van Staveren, W.A.; 
de Groot, L. Dietary Intake and Status of Folate and Vitamin B12 and Their Association with 
Homocysteine and Cardiovascular Disease in European Populations. Eur. J. Clin. Nutr. 2009, 63, 
18–30.  
4.  de Bree, A.; van Dusseldorp, M.; Brouwer, I.A.; van het Hof, K.H.; Steegers-Theunissen, R.P.M. 
Review Folate Intake in Europe: Recommended, Actual and Desired Intake. Eur. J. Clin. Nutr. 
1997, 51, 643–660.  
5.  Bergstrom,  L.  Nutrient  Losses  and  Gains  in  the  Preparation  of  Foods;  National  Food 
Administration: Sweden, Uppsala, 1994.  
6.  Mitchell, L.E.; Adzick, N.S.; Melchionne, J.; Pasquariello, P.S.; Sutton, L.N.; Whitehead, A.S. 
Spina bifida. Lancet 2004, 364, 1885–1895.  
7.  Gregory, J.F. Folate. In Food Chemistry; Fennema, O.R., Ed.; Marcel Dekker: New York, NY, 
USA, 1996; pp. 590–616.  Nutrients 2011, 3  
 
485 
8.  Mosley,  B.S.;  Cleves,  M.A.;  Siega-Riz,  A.M.;  Shaw,  G.M.;  Canfield,  M.A.;  Waller,  D.K.;  
Werler, M.M.; Hobbs, C.A. Neural Tube Defects and Maternal Folate Intake among Pregnancies 
Conceived after Folic acid Fortification in the United States. Am. J. Epidemiol. 2009, 169, 9–17.  
9.  Yang, Q.; Botto, L.D.; Erickson, J.D.; Berry, R.J.; Sambell, C.; Johansen, H.; Friedman, J.M. 
Improvement in Stroke Mortality in Canada and the United States, 1990 to 2002. Circulation 
2006, 113, 1335–1343. 
10.  Shirodaria, C.; Antoniades, C.; Lee, J.; Jackson, C.E.; Robson, M.D.; Francis, J.M.; Moat, S.J.; 
Ratnatunga, C.; Pillai, R.; Refsum, H.; Neubauer, S.; Channon, K.M. Global Improvement of 
Vascular  Function  and  Redox  State  with  Low-Dose  Folic  Acid.  Circulation  2007,  115,  
2262–2270. 
11.  Sanderson,  P.;  McNulty,  H.;  Mastroiacovo,  P.;  McDowell,  I.F.W.;  Melse-Boonstra,  A.;  
Finglas,  P.M.;  Gregory,  J.F.  Folate  Bioavailability:  UK  Food  Standards  Agency  Workshop 
Report. Br. J. Nutr. 2003, 90, 473–479.  
12.  CDC. Water-Soluble Vitamins & Related Biochemical Compounds; Centers for Disease Control 
and  Prevention:  Atlanta,  GA,  USA.  Available  online:  http://www.cdc.gov/nutritionreport/ 
part_1.html (accessed on 13 July 2009).  
13.  Hannon-Fletcher,  M.P.;  Armstrong,  N.C.;  Scott,  J.M.;  Pentieva,  K.;  Bradbury,  I.;  Ward,  M.; 
Strain, J.J.; Dunn, A.A.; Molloy, A.M.; Kerr, M.A.; McNulty, H. Determining Bioavailability of 
Food Folates in a Controlled Intervention Study. Am. J. Clin. Nutr. 2004, 80, 911–918.  
14.  Brouwer,  I.A.;  van  Dusseldorp,  M.;  West,  C.;  Meyboom,  S.;  Thomas,  C.M.G.;  Duran,  M.;  
van  het  Hof,  K.H.;  Eskes,  T.K.A.B.;  Hautvast,  G.A.J.;  Steegers-Theunissen,  R.P.M.  Dietary 
Folate  from  Vegetables  and  Citrus  Fruit  Decreases  Plasma  Homocysteine  Concentrations  in 
Humans in a Dietary Controlled trial. J. Nutr. 1999, 129, 1135–1139.  
15.  Gregory, J.F. The Bioavailability of Folate. In Folate in Health and Disease; Bailey, L.B., Ed.; 
Marcel Dekker: New York, NY, USA, 1995; pp. 195–235.  
16.  Melse-Boonstra,  A.;  Verhoef,  P.;  West,  C.  Quantifying  Folate  Bioavailability:  A  Critical 
Appraisal of Methods. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7, 539–545.  
17.  Wright, A.J.A.; Finglas, P.M.; Dainty, J.R.; Hart, D.J.; Wolfe, C.A.; Southon, S.; Gregory, J.F. 
Single  Oral  Doses  of  C-13  Forms  of  Pteroylmonoglutamic  Acid  and  5-Formyltetrahydrofolic 
Acid Elicit Differences in Short-Term Kinetics of Labelled and Unlabelled Folates in Plasma: 
Potential  Problems  in  Interpretation  of  Folate  Bioavailability  Studies.  Br.  J.  Nutr.  2003,  90,  
363–371.  
18.  Wright, A.J.A.; Finglas, P.M.; Dainty, J.R.; Wolfe, C.A.; Hart, D.J.; Wright, D.M.; Gregory, J.F. 
Differential Kinetic Behavior and Distribution for Pteroylglutamic Acid and Reduced Folates: A 
Revised Hypothesis of the Primary Site of PteGlu Metabolism in Humans. J. Nutr. 2005, 135,  
619–623.  
19.  Wright,  A.J.A.;  King,  M.J.;  Wolfe,  C.A.;  Powers,  H.J.;  Finglas,  P.M.  Comparison  of  
(6S)-5-methyltetrahydrofolic Acid v. Folic Acid as the Reference Folate in Longer-term Human 
Dietary  Intervention  Studies  Assessing  the  Relative  Bioavailability  of  Natural  Food  Folates: 
Comparative Changes in Folate Status Following a 16-week Placebo-controlled Study in Healthy 
Adults. Br. J. Nutr. 2010, 103, 724–729.  Nutrients 2011, 3  
 
486 
20.  Pfeiffer, C.M.; Fazili, Z.; Zhang, M. Folate Analytical Methodology. In Folate in Health and 
Disease, 2nd ed.; Bailey, L.B., Ed.; CRC Press: Boca Raton, FL, USA, 2010; pp. 517–574. 
21.  Finglas,  P.M.;  Scott,  K.J.;  Witthoft,  C.M.;  van  den  Berg,  H.;  de  Froidmont-Gortz,  I.  
The  Certification of the  Mass  Fraction of  Vitamins in  Four Reference Materials: Wholemeal 
Flour  (CRM  121),  Milk  powder  (CRM  421),  Lyophilised  Mixed  Vegetables  (CRM  485)  and 
Lyophilised  Pig’s  Liver  (CRM  487);  EUR-Report  18320;  Office  for  Official  Publications, 
Commission of the European Union: Luxembourg, Luxembourg, 1999.  
22.  Vahteristo, L.T.; Finglas, P.M.; Witthoft, C.M.; Wigertz, K.; Seale, R.; De Froidmont-Gortz, I. 
Third EU MAT Intercomparison Study on Food Folate Analysis Using HPLC Procedures. Food 
Chem. 1996, 57, 109–111.  
23.  Caudill, M.A. Folate Bioavailability: Implications for Establishing Dietary Recommendations and 
Optimizing status. Am. J. Clin. Nutr. 2010, 91, 1455S–1460S.  
24.  Kim, Y.I. Folate and Colorectal Cancer: An Evidence-Based Critical Review. Mol. Nutr. Food 
Res. 2007, 51, 267–292.  
25.  Mason, J.B.; Dickstein, A.; Jacques, P.F.; Haggarty, P.; Selhub, J.; Dallal, G.; Rosenberg, I.H.  
A Temporal Association between Folic Acid Fortification and an Increase in Colorectal Cancer 
Rates May Be Illuminating Important Biological Principles: A Hypothesis. Cancer Epidemiol. 
Biomarkers Prev. 2007, 16, 1325–1329.  
26.  Smith, A.D.; Kim, Y.-I.; Refsum, H. Is Folic Acid Good for Everyone? Am. J. Clin. Nutr. 2008, 
87, 517–533.  
27.  Halsted, C.H. Intestinal Absorption of Dietary Folates. In Folic Acid Metabolism in Health and 
Disease; Picciano, M.F., Gregory, J.F., Stokstad, E.L., Eds.; Wiley-Liss: New York, NY, USA, 
1990; pp. 23–46.  
28.  Zhao,  R.;  Matherly,  L.H.;  Goldman,  I.D.  Membrane  Transporters  and  Folate  Homeostasis: 
Intestinal Absorption and Transport into Systemic Compartments and Tissues. Expert Rev. Mol. 
Med. 2009, 11, e4, doi:10.1017/S1462399409000969. 
29.  Aufreiter, S.; Gregory, J.F., III; Pfeiffer, C.M.; Fazili, Z.; Kim, Y.-I.; Marcon, N.; Kamalaporn, P.; 
Pencharz, P.B.; O’Connor, D.L. Folate is Absorbed across the Colon of Adults: Evidence from 
Cecal Infusion of 13C-Labeled [6S]-5-formyltetrahydrofolic Acid. Am. J. Clin. Nutr. 2009, 90, 
116–123. 
30.  Camilo, E.; Zimmerman, J.; Mason, J.B.; Golner, B.; Russell, R.; Selhub, J.; Rosenberg, I.H. 
Folate Synthesized by Bacteria in the Human Upper Small Intestine is Assimilated by the Host. 
Gastroenterology 1996, 110, 991–998.  
31.  Asrar, F.M.; O’Connor, D.L. Bacterially Synthesized Folate and Supplemental Folic Acid Are 
Absorbed across the Large Intestine of Piglets. J. Nutr. Biochem. 2005, 16, 587–593.  
32.  Gregory,  J.F.;  Williamson,  J.;  Liao,  J.F.;  Bailey,  L.B.;  Toth,  J.P.  Kinetic  Model  of  Folate 
Metabolism in Nonpregnant Women Consuming [H-2(2)]Folic Acid: Isotopic Labeling of Urinary 
Folate  and  the  Catabolite  Para-acetamidobenzoylglutamate  Indicates  Slow,  Intake-Dependent, 
Turnover of Folate Pools. J. Nutr. 1998, 128, 1896–1906.  
33.  Herbert, V. Recommended Dietary Intakes (RDI) of Folate in Humans. Am. J. Clin. Nutr. 1987, 
45, 661–670.  Nutrients 2011, 3  
 
487 
34.  Lin, Y.; Dueker, S.R.; Follett, J.R.; Fadel, J.G.; Arjomand, A.; Schneider, P.D.; Miller, J.W.; 
Green, R.; Buchholz, B.A.; Vogel, J.S.; Phair, R.D.; Clifford, A.J. Quantitation of in vivo Human 
Folate Metabolism. Am. J. Clin. Nutr. 2004, 80, 680–691.  
35.  Wagner, C. Biochemical Role of Folate in Cellular Metabolism. In Folate in Health and Disease; 
Bailey, L.B., Ed.; Clinical Nutrition in Health and Disease 1; Marcel Dekker: New York, NY, 
USA, 1995; pp. 23–42.  
36.  Tamura,  T.;  Picciano,  M.F.  Folate  and  Human  Reproduction.  Am.  J.  Clin.  Nutr.  2006,  83,  
993–1016.  
37.  Reed, M.C.; Nijhout, H.F.; Neuhouser, M.L.; Gregory, J.E.; Shane, B.; James, S.J.; Boynton, A.; 
Ulrich,  C.M.  A  Mathematical  Model  Gives  Insights  into  Nutritional  and  Genetic  Aspects  of 
Folate-Mediated One-Carbon Metabolism. J. Nutr. 2006, 136, 2653–2661. 
38.  Ohrvik, V. Folate Bioavailability. In-vitro Experiments and In-vivo Trials. Ph.D. Thesis, Swedish 
University of Agricultural Sciences, Uppsala, Sweden, 2009.  
39.  Gregory, J.F.; Caudill, M.A.; Opalko, F.J.; Bailey, L.B. Kinetics of Folate Turnover in Pregnant 
Women  (Second  Trimester)  and  Nonpregnant  Controls  during  Folic  Acid  Supplementation: 
Stable-Isotopic Labeling of Plasma Folate, Urinary Folate and Folate Catabolites Shows Subtle 
Effects of Pregnancy on Turnover of Folate Pools. J. Nutr. 2001, 131, 1928–1937.  
40.  Witthoft,  C.;  Stralsjo,  L.;  Berglund,  G.;  Lundin,  E.  A  Human  Model  to  Determine  Folate 
Bioavailability from Food: A Pilot Study for Evaluation. Scand. J. Nutr. 2003, 47, 6–18.  
41.  Pfeiffer, C.M.; Rogers, L.M.; Bailey, L.B.; Gregory, J.F. Absorption of Folate from Fortified 
Cereal-Grain Products and of Supplemental Folate Consumed with or Without Food Determined 
Using a Dual-Label Stable-Isotope Protocol. Am. J. Clin. Nutr. 1997, 66, 1388–1397.  
42.  Rogers, L.M.; Pfeiffer, C.M.; Bailey, L.B.; Gregory, J.F. A Dual-Label Stable-Isotopic Protocol Is 
Suitable for Determination of Folate Bioavailability in Humans: Evaluation of Urinary Excretion 
and Plasma Folate Kinetics of Intravenous and Oral Doses of [C-13(5)] and [H-2(2)]Folic Acid.  
J. Nutr. 1997, 127, 2321–2327.  
43.  Gregory, J.F.; Quinlivan, E.P. In vivo Kinetics of Folate Metabolism. Ann. Rev. Nutr. 2002, 22, 
199–220.  
44.  Witthoft, C.M.; Arkbage, K.; Johansson, M.; Lundin, E.; Berglund, G.; Zhang, J.X.; Lennernas, H.; 
Dainty,  J.R.  Folate  Absorption  from  Folate-Fortified  and  Processed  Foods  Using  a  Human 
Ileostomy Model. Br. J. Nutr. 2006, 95, 181–187.  
45.  Konings,  E.J.M.;  Troost,  F.J.;  Castenmiller,  J.J.M.;  Roomans,  H.H.S.;  van  den  Brandt,  P.A.;  
Saris, W.H.M. Intestinal Absorption of Different Types of Folate in Healthy Subjects with an 
Ileostomy. Br. J. Nutr. 2002, 88, 235–242.  
46.  Ohrvik, V.E.; Buttner, B.E.; Rychlik, M.; Lundin, E.; Witthoft, C.M. Folate Bioavailability from 
Breads and a Meal Assessed with a Human Stable-Isotope Area under the Curve and Ileostomy 
Model. Am. J. Clin. Nutr. 2010, 92, 532–538. 
47.  Buttner, B.E.; Ohrvik, V.E.; Witthoft, C.M.; Rychlik, M. Quantification of Isotope-Labelled and 
Unlabelled Folates in Plasma, Ileostomy and Food Samples. Anal. Bioanal. Chem. 2011, 399, 
429–439. Nutrients 2011, 3  
 
488 
48.  Wilcken, B.; Bamforth, F.; Li, Z.; Zhu, H.; Ritvanen, A.; Redlund, M.; Stoll, C.; Alembik, Y.; 
Dott,  B.;  Czeizel,  A.E.;  et  al.  Geographical  and  Ethnic  Variation  of  the  677C>T  Allele  of  
5,10 Methylenetetrahydrofolate Reductase (MTHFR): Findings from over 7000 Newborns from 
16 Areas World Wide. J. Med. Genet. 2003, 40, 619–625.  
49.  Rozen, R. Folate and Genetics. J. Food Sci. 2004, 69, S65–S67.  
50.  Gregory, J.F.; Quinlivan, E.P.; Davis, S.R. Integrating the Issues of Folate Bioavailability, Intake 
and Metabolism in the Era of Fortification. Trends Food Sci. Technol. 2005, 16, 229–240.  
51.  Morin,  I.;  Devlin,  A.M.;  Leclerc,  D.;  Sabbaghian,  N.;  Halsted,  C.H.;  Finnell,  R.;  Rozen,  R. 
Evaluation of Genetic Variants in the Reduced Folate Carrier and in Glutamate Carboxypeptidase 
II for Spina Bifida Risk. Mol. Genet. Metab. 2003, 79, 197–200.  
52.  Tozer, T.; Rowland, M. Introduction to Pharmacokinetics and Pharmacodynamics; Lippincott 
Williams & Wilkins: Baltimore County, MD, USA, 2006. 
53.  Gregory, J.F. Bioavailability of Folate. Eur. J. Clin. Nutr. 1997, 51, S54–S59.  
54.  Bouckeart, K.P.; Slimani, N.; Nicolas, G.; Vignat, J.; Wright, A.J.A.; Roe, M.; Witthoft, C.M.; 
Finglas,  P.M.  Critical  Evaluation  of  Folate  Data  in  European  and  International  Databases: 
Recommendations for Standardization in International Nutritional Studies. Mol. Nutr. Food Res. 
2011, 55, 166–180. 
55.  AACC International. Approved Methods of Analysis, 11th ed. Method 86-47.01. Total Folate in 
Cereal  Products—Microbiological  Assay  Using  Trienzyme  Extraction;  AACC  International:  
St. Paul, MN, USA, 2000; doi:10.1094/AACCIntMethod-86-47.01. 
56.  DeVries, J.W.; Keagy, P.M.; Hudson, C.A.; Rader, J.I. AACC Collaborative Study of a Method 
for  Determining  Total  Folate  in  Cereal  Products—Microbiological  Assay  Using  Trienzyme 
Extraction (AACC method 86-47). Cereal Food World 2001, 46, 216–219. 
57.  Cho, S.; Choi, Y.; Lee, J.; Eitenmiller, R.R. Optimization of Enzyme Extractions for Total Folate 
in Cereals Using Response Surface Methodology. J. Agric. Food Chem. 2010, 58, 10781–10786. 
58.  Riddell,  L.J.;  Chisholm,  A.;  Williams,  S.;  Mann,  J.I.  Dietary  Strategies  for  Lowering 
Homocysteine Concentrations. Am. J. Clin. Nutr. 2000, 71, 1448–1454.  
59.  Ohrvik, V.E.; Olsson, J.C.; Sundberg, B.E.; Witthoft, C.M. Effect of 2 pieces of nutritional advice 
on folate status in Swedish women: A randomized controlled trial. Am. J. Clin. Nutr. 2009, 89, 
1053–1058.  
60.  Vahteristo, L.; Kariluoto, S.; Barlund, S.; Karkkainen, M.; Lamberg-Allardt, C.; Salovaara, H.; 
Piironen,  V.  Functionality  of  Endogenous  Folates  from  Rye  and  Orange  Juice  Using  Human 
in vivo Model. Eur. J. Nutr. 2002, 41, 271–278.  
61.  Winkels, R.M.; Brouwer, I.A.; Siebelink, E.; Katan, M.B.; Verhoef, P. Bioavailability of Food 
Folates is 80% of that of Folic Acid. Am. J. Clin. Nutr. 2007, 85, 465–473.  
62.  Venn, B.J.; Mann, J.I.; Williams, S.M.; Riddell, L.J.; Chisholm, A.; Harper, M.J.; Aitken, W. 
Dietary Counseling to Increase Natural Folate Intake: A Randomized, Placebo-Controlled Trial in 
Free-living Subjects to Assess Effects on Serum Folate and Plasma Total Homocysteine. Am. J. 
Clin. Nutr. 2002, 76, 758–765.  
63.  Fenech, M.; Noakes, M.; Clifton, P.; Topping, D. Aleurone Flour Increases Red-Cell Folate and 
Lowers Plasma Homocyst(E)Ine Substantially in Man. Br. J. Nutr. 2005, 93, 353–360.  Nutrients 2011, 3  
 
489 
64.  Pentieva, K.; McNulty, H.; Reichert, R.; Ward, M.; Strain, J.J.; McKillop, D.J.; McPartlin, J.M.; 
Connolly,  E.;  Molloy,  A.;  Kramer,  K.;  Scott,  J.M.  The  Short-term  Bioavailabilities  of  
[6S]-5-Methyltetrahydrofolate  and  Folic  Acid  Are  Equivalent  in  Men.  J.  Nutr.  2004,  134,  
580–585.  
65.  Fenech, M.; Noakes, M.; Clifton, P.; Topping, D. Aleurone Flour is a Rich Source of Bioavailable 
Folate in Humans. J. Nutr. 1999, 129, 1114–1119.  
66.  Cuskelly, G.J.; McNulty, H.; Scott, J.M. Effect of Increasing Dietary Folate on Red-Cell Folate: 
Implications for Prevention of Neural Tube Defects. Lancet 1996, 347, 657–659.  
67.  Broekmans,  W.M.R.;  Klopping-Ketelaars,  I.A.A.;  Schuurman,  C.R.W.C.;  Verhagen,  H.;  
van den Berg, H.; Kok, F.J.; van Poppel, G. Fruits and Vegetables Increase Plasma Carotenoids 
and Vitamins and Decrease Homocysteine in Humans. J. Nutr. 2000, 130, 1578–1583.  
68.  Bogers, R.P.; Dagnelie, P.C.; Bast, A.; van Leeuwen, M.; van Klaveren, J.D.; van den Brandt, P.A. 
Effect  of  Increased  Vegetable  and  Fruit  Consumption  on  Plasma  Folate  and  Homocysteine 
Concentrations. Nutrition 2007, 23, 97–102.  
69.  Ashfield-Watt,  P.A.L.;  Whiting,  J.M.;  Clark,  Z.E.;  Moat,  S.J.;  Newcombe,  R.G.;  Burr,  M.L.; 
McDowell, I.F.W. A Comparison of the Effect of Advice to Eat Either ―5-A-Day‖ Fruit and 
Vegetables or Folic Acid-Fortified Foods on Plasma Folate and Homocysteine. Eur. J. Clin. Nutr. 
2003, 57, 316–323.  
70.  Prinz-Langenohl, R.; Bronstrup, A.; Thorand, B.; Hages, M.; Pietrzik, K. Availability of Food 
Folate in Humans. J. Nutr. 1999, 129, 913–916.  
71.  Enghardt-Barbieri,  H.;  Lindvall,  C.  Swedish  Nutrition  Recommendations  Objectified  
(SNO)—Basis  for  General  Advice  on  Food  Consumption  for  Healthy  Adults;  National  Food 
Administration: Sweden, Uppsala, 2005.  
72.  Summers,  C.M.;  Mitchell,  L.E.;  Stanislawska-Sachadyn,  A.;  Baido,  S.F.;  Blair,  I.A.;  
Von Feldt, J.M.; Whitehead, A.S. Genetic and Lifestyle Variables Associated with Homocysteine 
Concentrations and the Distribution of Folates Derivatives in Healthy Premenopausal Women. 
Birth Defects Res. A 2010, 88, 679–688. 
73.  McKinley, M.C.; Strain, J.J.; McPartlin, J.; Scott, J.M.; McNulty, H. Plasma Homocysteine Is Not 
Subject to Seasonal Variation. Clin. Chem. 2001, 47, 1430–1436.  
74.  Clarke,  R.;  Woodhouse,  P.;  Ulvik,  A.;  Frost,  C.;  Sherliker,  P.;  Refsum,  H.;  Ueland,  P.M.;  
Khaw, K.-T. Variability and determinants of Total Homocysteine Concentrations in Plasma in an 
Elderly Population. Clin. Chem. 1998, 44, 102–107.  
75.  Garg, U.C.; Zheng, Z.-J.; Folsom, A.R.; Moyer, Y.S.; Tsai, M.Y.; McGovern, P.; Eckfeldt, J.H. 
Short-Term  and  Long-Term  Variability  of  Plasma  Homocysteine  Measurement.  Clin.  Chem. 
1997, 43, 141–145.  
76.  Antoniades,  C.;  Shirodaria,  C.;  Leeson,  P.;  Baarholm,  O.A.;  Van-Assche,  T.;  Stefanadis,  C.; 
Refsum, H.; Channon, K.M. MTHFR 677 C>T Polymorphism Reveals Functional Importance for 
Methyltetrahydrofolate,  Not  Homocysteine,  in  Regulation  of  Vascular  Redox  State  and 
Endothelial Function in Human Atherosclerosis. Circulation 2009, 119, 2507–2515. 
77.  Tamura,  T.;  Stokstad,  E.L.  Availability  of  Food  Folate  in  Man.  Br.  J.  Haematol.  1973,  25,  
513–532.  Nutrients 2011, 3  
 
490 
78.  Achon, M.; Arrate, A.; Alonso-Aperte, E.; Varela-Moreiras, G. Plasma Folate Concentrations 
after  a Single Dose Ingestion  of  Whole and Skimmed Folic Acid Fortified Milks  in Healthy 
Subjects. Eur. J. Nutr. 2011, 50, 119–125.  
79.  Colman,  N.;  Green,  R.;  Metz,  J.  Prevention  of  Folate  Deficiency  by  Food  Fortification.  II. 
Absorption of Folic Acid from Fortified Staple Foods. Am. J. Clin. Nutr. 1975, 28, 459–464.  
80.  Finglas, P.M.; Witthoft, C.M.; Vahteristo, L.; Wright, A.J.A.; Southon, S.; Mellon, F.A.; Ridge, B.; 
Maunder, P. Use of an Oral/Intravenous Dual-Label Stable-Isotope Protocol to Determine Folic 
Acid Bioavailability from Fortified Cereal Grain Foods in Women. J. Nutr. 2002, 132, 936–939.  
81.  Wei,  M.M.;  Bailey,  L.B.;  Toth,  J.P.;  Gregory,  J.F.  Bioavailability  for  Humans  of  
Deuterium-Labeled  Monoglutamyl  and  Polyglutamyl  Folates  Is  Affected  by  Selected  Foods.  
J. Nutr. 1996, 126, 3100–3108.  
82.  Gregory,  J.F.;  Bhandari,  S.D.;  Bailey,  L.B.;  Toth,  J.P.;  Baumgartner,  T.G.;  Cerda,  J.J.  
Relative  Bioavailability  of  Deuterium-Labeled  Monoglutamyl  and  Hexaglutamyl  Folates  in 
Human-Subjects. Am. J. Clin. Nutr. 1991, 53, 736–740.  
83.  Buchholz, B.A.; Arjomand, A.; Dueker, S.R.; Schneider, P.D.; Clifford, A.J.; Vogel, J.S. Intrinsic 
Erythrocyte Labeling and Attomole Pharmacokinetic Tracing of 14C-Labeled Folic Acid with 
Accelerator Mass Spectrometry. Anal. Biochem. 1999, 269, 348–352.  
84.  Wigertz,  K.  Milk  Folates—Characterisation  and  Availability.  Ph.D.  Thesis,  Lund  University, 
Lund, Sweden, 1997.  
85.  Ashokkumar,  B.;  Mohammed,  Z.M.;  Vaziri,  N.D.;  Said,  H.M.  Effect  of  Folate 
Oversupplementation on Folate Uptake by Human Intestinal and Renal Epithelial Cells. Am. J. 
Clin. Nutr. 2007, 86, 159–166.  
86.  Ohrvik,  V.E.;  Buttner,  B.E.;  Rychlik,  M.;  Lundin,  E.;  Witthoft,  C.M.  The  Bioavailability  of  
Folic  Acid  and  Reduced  Folate  Bioavailability  from  Foods  and  Pharmaceutical  Preparations 
Assessed  With  a  Human  Stable-Isotope  Area  under  the  Curve  and  Ileostomy  Model.  2011,  
unpublished work.  
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is an open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 